Full-Time

Sr. Manager

Quality Control, Reference Standards

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$180k - $187kAnnually

Senior

San Carlos, CA, USA

Hybrid position.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Bachelor’s, Master’s, or Ph.D. in Biochemistry, Chemistry, or a related field. Ph.D. with 5+ years of relevant QC experience, or MS/BS with 8+ years of experience, including significant experience in reference standard management.
  • Strong background in cGMP and ICH regulatory guidance associated with reference standards and critical reagents.
  • Experience working with biochemistry, immunoassay, or microbiological assay techniques.
  • Familiarity with statistical software (e.g., JMP) for data analysis, trending, and process optimization.
  • Excellent organizational and project management skills, with the ability to handle multiple projects under tight timelines.
  • Strong written and verbal communication skills, including the ability to work effectively in cross-functional teams.
  • Proficiency in LIMS and other laboratory data management systems is preferred.
Responsibilities
  • Oversee the implementation and maintenance of the reference standards and critical reagent program, ensuring compliance with cGMP and ICH guidelines.
  • Support the development of global business practices, policies, and standards for reference standards and critical reagents, including qualification, requalification, and inventory management.
  • Collaborate in the authoring and review of technical protocols, qualification reports, requalification reports, and Certificates of Analysis (CoAs) related to reference standards. Ensure timely updates to SOPs and other relevant documentation.
  • Manage supply chain logistics, including inventory and space planning, to ensure a continuous supply of qualified reference standards and critical reagents.
  • Serve as a key point of contact within Vaxcyte QC and with external partners, fostering productive collaborations to support the company's vaccine programs.
  • Provide technical guidance on assay qualification and validation to meet regulatory standards, and review test methods and release documentation for reference standards.
  • Review and manage deviations, OOS/OOT results, and conduct risk assessments related to reference standards and critical reagents.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop broad-spectrum vaccines that can significantly reduce the impact of bacterial diseases on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

19%

1 year growth

58%

2 year growth

129%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?